Curated News
By: NewsRamp Editorial Staff
April 01, 2026
NanoViricides Advances MPox Treatment with Phase II Trial in DRC
TLDR
- NanoViricides' Phase II trial for NV-387 against MPox offers investors early access to a potential breakthrough antiviral with Orphan Drug Designation pending.
- NanoViricides will begin a Phase II trial in the DRC in April 2026 to evaluate NV-387's safety and efficacy against Clade I MPox.
- This clinical trial advances a potential treatment for MPox, aiming to improve global health outcomes and combat viral diseases more effectively.
- NanoViricides is testing a broad-spectrum nanoviricide that could treat multiple viruses, representing a novel approach in antiviral drug development.
Impact - Why it Matters
This news matters because it highlights a critical development in the global fight against infectious diseases like MPox, which has seen outbreaks in recent years, particularly in regions like Africa. The Phase II trial of NV-387 in the Democratic Republic of Congo could lead to new antiviral treatments, addressing a significant public health need. MPox, caused by a virus related to smallpox, can cause severe illness and has limited treatment options, making advancements in this area vital for outbreak control and patient care. If successful, NV-387's broad-spectrum potential might also offer solutions for other viral infections, such as COVID-19 and influenza, enhancing pandemic preparedness. For investors and the healthcare community, this represents progress in biotechnology innovation, with potential implications for global health security and economic opportunities in the pharmaceutical sector.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biotechnology company, has announced a significant milestone in its antiviral development pipeline. The company's lead drug candidate, NV-387, is poised to enter a Phase II clinical trial in the Democratic Republic of Congo (DRC) for the treatment of MPox, specifically targeting the Clade I variant. With site preparation and staff training scheduled for early April 2026, this trial has already received approval from DRC regulatory authorities, marking a crucial step forward. NanoViricides is also advancing regulatory development and seeking Orphan Drug Designation from the U.S. FDA to bolster its efforts against this infectious disease. For more details, the full press release is available at https://ibn.fm/4Ckhk.
NanoViricides operates on a unique business model, licensing proprietary nanoviricide™ technology from TheraCour Pharma, Inc. to develop special-purpose nanomaterials for antiviral therapy. The company's platform targets a broad spectrum of viral infections, including RSV, COVID-19, influenza, and MPox, with NV-387 designed as a broad-spectrum antiviral. Beyond MPox, NanoViricides is developing other candidates like NV-HHV-1 for shingles and has programs for diseases such as HIV, hepatitis C, and Ebola. The company emphasizes that its technology, based on TheraCour's nanomedicine, holds exclusive licenses for various viruses, though it notes the inherent risks and lengthy timelines typical of drug development. Investors can stay updated through the company's newsroom at https://ibn.fm/NNVC.
This news release was distributed via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which enhances press release syndication and social media distribution to reach a wide audience. InvestorWire provides services like article syndication to over 5,000 outlets and tailored corporate communications solutions, ensuring maximum impact for companies like NanoViricides. For more information, visit https://www.InvestorWire.com. The announcement underscores NanoViricides' commitment to advancing antiviral treatments, leveraging its innovative technology to address global health challenges, with the upcoming Phase II trial in the DRC representing a pivotal moment in its fight against MPox and potential broader applications.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances MPox Treatment with Phase II Trial in DRC
